[1] Calazans JA, Queiroz BL. The adult mortality profile by cause of death in 10 Latin American countries (2000-2016). Rev Panam Salud Publica. 2020; 44: e1
[2] International Diabetes Federation. IDF Diabetes Atlas Ninth Edition; 2019. https://www.diabetesatlas.org/en/. Accessed on Dec 1, 2020
[3] Caballero AE. Diabetes in the Hispanic or Latino population: genes, environment, culture, and more. Curr Diab Rep. 2005; 5: 217–25
[4] Aschner P, Aguilar-Salinas C, Aguirre L, et al. Diabetes in South and Central America: an update. Diabetes Res Clin Pract. 2014; 103: 238–43
[5] Shen J, Kondal D, Rubinstein A, et al. A Multiethnic Study of Pre-Diabetes and Diabetes in LMIC. Glob Heart. 2016; 11: 61–70
[6] Gallardo-Rincon H, Cantoral A, Arrieta A, et al. Review: Type 2 diabetes in Latin America and the Caribbean: Regional and country comparison on prevalence, trends, costs and expanded prevention. Prim Care Diabetes. 2020; S1751-9918(20): 30286–2
[7] Hofman AA. The Economic Development of Latin America in the Twentieth Century. UK and USA. Edward Elgar Publishing Limited, 2000
[8] Blasco-Blasco M, Puig-Garcia M, Piay N, Lumbreras B, Hernandez-Aguado I, Parker LA. Barriers and facilitators to successful management of type 2 diabetes mellitus in Latin America and the Caribbean: A systematic review. PLoS One. 2020; 15: e0237542
[9] Vencio S, Paldanius PM, Bluher M, Giannella-Neto D, Caiado-Vencio R, Strain WD. Understanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetes. Diabetol Metab Syndr. 2017; 9: 46
[10] Aviles-Santa ML, Monroig-Rivera A, Soto-Soto A, Lindberg NM. Current State of Diabetes Mellitus Prevalence, Awareness, Treatment, and Control in Latin America: Challenges and Innovative Solutions to Improve Health Outcomes Across the Continent. Curr Diab Rep. 2020; 20: 62
[11] Lopez Stewart G, Tambascia M, Rosas Guzman J, Etchegoyen F, Ortega Carrion J, Artemenko S. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica. 2007; 22: 12-20
[12] Irazola V, Rubinstein A, Bazzano L, et al. Prevalence, awareness, treatment and control of diabetes and impaired fasting glucose in the Southern Cone of Latin America. PLoS One. 2017; 12: e0183953
[13] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577–89
[14] Cai X, Gao X, Yang W, Han X, Ji L. Efficacy and Safety of Initial Combination Therapy in Treatment-Naive Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. Diabetes Ther. 2018; 9: 1995–2014
[15] Matthews DR, Paldanius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394: 1519–29
[16] Del Prato S, Foley JE, Kothny W, et al. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabet Med. 2014; 31: 1178–84
[17] Matthews DR, Paldanius PM, Stumvoll M, et al. A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. Diabetes Obes Metab. 2019; 21: 2240–7
[18] Chan JC, Vencio S, Proot P et al. Screening values of glycated haemoglobin suggest regional barriers in detecting T2DM early: Analysis of the VERIFY study. Poster presented at Internalthional Diabetes Federation Congress 2019. OP-0279. https://doi.org/10.26226/morressier.5d9b622bea541d6ca8493b20
[19] Chan JC, Paldánius PM, Mathieu C et al. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study. Diabetes Obes Metab. 2021; 23(1):245–51
[20] Filozof C, Gonzalez C, Sereday M, Mazza C, Braguinsky J. Obesity prevalence and trends in Latin-American countries. Obes Rev. 2001; 2: 99–106
[21] Association of Latin America Diabetes. ALAD guidelines on the diagnosis, control and treatment of type 2 diabetes mellitus with medicine based on evidence. Edition. 2019; https://www.revistaalad.com/guias/5600AX191_guias_alad_2019.pdf. Accessed on Dec 1, 2020
[22] Mendivil CO, Marquez-Rodriguez E, Angel ID, et al. Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study. Curr Med Res Opin. 2014; 30: 1769–76
[23] Machado-Duque ME, Ramirez-Riveros AC, Machado-Alba JE. Effectiveness and clinical inertia in patients with antidiabetic therapy. Int J Clin Pract. 2017; 71
[24] Guzman JR, Lyra R, Aguilar-Salinas CA, et al. Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association. Rev Panam Salud Publica. 2010; 28: 463–71
[25] Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43: 487–93
[26] Bertoluci MC, Salles JEN, Silva-Nunes J, et al. Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. Diabetol Metab Syndr. 2020; 12: 45